The 2NN study - CD8 T cells

More documents

Recommendations

Info

percentage of patients 100 75 50 25 0 pVL < 50 copies/mL OT * p=0.064 0 2 4 8 12 18 24 36 48 weeks after start allocated treatment NVP-od NVP-bd Frank van Leth 12 EFV NVP + EFV NVP-od n=208 194 161 156 151 147 142 88.7 % NVP-bd n=378 336 306 305 291 282 275 81.5 % EFV n=381 342 329 322 310 299 289 86.8 % NVP + EFV n=199 170 149 145 137 130 127 79.5 % *
number of CD4+ -<strong>cells</strong> (median (IQR) /mm 3 ) 300 200 100 0 Increase in CD4 <strong>cells</strong> OT -100 0 2 4 8 12 24 36 48 weeks after start allocated treatment * p=0.912 NVP-od n=203 179 155 147 144 141 137 NVP-bd n=360 321 286 294 278 266 267 EFV n=365 331 317 313 300 287 278 NVP + EFV n=192 161 141 137 130 122 122 NVP-od NVP-bd Frank van Leth 13 * EFV NVP + EFV
Page 1 and 2: The 2NN study A randomised comparat
Page 3 and 4: NVP 400 mg od n=220 Trial design 12
Page 5 and 6: Methods • All analyses Intention-
Page 7 and 8: Baseline characteristics NVP-od NVP
Page 9 and 10: % patie nts with virologic success
Page 11: percentage of patients 100 75 50 25
Page 15 and 16: Grade 3 or 4 laboratory toxicities
Page 17 and 18: plasma HDL mmol/L 1.50 1.25 1.00 0.
Page 19 and 20: Conclusions • NVP and EFV have co
Page 21 and 22: Acknowledgements (2) Other investig

The 2NN study - CD8 T cells

Create successful ePaper yourself

Delete template?

Save as template?